trending Market Intelligence /marketintelligence/en/news-insights/trending/A24JNWZC8buvv-oj2WosUg2 content esgSubNav
In This List

Biohaven Pharmaceutical files for IPO of up to $100M

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Biohaven Pharmaceutical files for IPO of up to $100M

Biohaven Pharmaceutical Holding Co. Ltd. filed for an IPO of up to $100 million with the U.S. SEC.

The biopharmaceutical company also applied to list on the NYSE under the symbol BHVN, according to the April 7 filing.

Morgan Stanley & Co. LLC and Piper Jaffray & Co. are acting as representatives for the underwriters of the proposed offering, which include Barclays Capital Inc., William Blair & Co. LLC and Needham & Co. LLC.